Ceftriaxone
- Generic Name
- Ceftriaxone
- Brand Names
- Rocephin
- Drug Type
- Small Molecule
- Chemical Formula
- C18H18N8O7S3
- CAS Number
- 73384-59-5
- Unique Ingredient Identifier
- 75J73V1629
- Background
Ceftriaxone is a broad-spectrum third-generation cephalosporin antibiotic. It has a very long half-life compared to other cephalosporins and is high penetrable into the meninges, eyes, and inner ear. Ceftriaxone has broader and stronger gram-negative coverage then first or second-generation cephalosporins, but worse activity against methicillin-susceptible S...
- Indication
Ceftriaxone is used for the treatment of the infections (respiratory, skin, soft tissue, UTI, ENT) caused by susceptible organisms. Organisms that are generally susceptible to ceftriaxone include S. pneumoniae, S. pyogenes (group A beta-hemolytic streptococci), coagulase-negative staphylococci, Some Enterobacter spp, H. influenzae, N. gonorrhoeae, P. mirabil...
- Associated Conditions
- Abscess Brain, Bacterial Endocarditis, Bacterial Infections, Bacterial Sinusitis, Bone and Joint Infections, Chancroid, Community Acquired Pneumonia (CAP), Conjunctivitis gonococcal neonatal, Epididymitis, Epiglottitis, Gonococcal arthritis, Gonococcal infection of pharynx, Gonococcal pelvic inflammatory disease, Intraabdominal Infections, Lower respiratory tract infection bacterial, Lyme Neuroborreliosis, Meningitis, Bacterial, Ophthalmia neonatorum due to gonococcus, Postoperative Infections, Prosthetic Joint Infections, Sepsis Bacterial, Septic Arthritis, Shigellosis, Skin and Subcutaneous Tissue Bacterial Infections, Syphilis, Vulvovaginitis gonococcal, Whipple Disease, Bacterial otitis media, Complicated Urinary Tract Infection caused by susceptible bacteria, Disease caused by Salmonella typhi, Susceptible Bacterial Infections, Uncomplicated Gonorrhea, Uncomplicated Urinary tract infection bacterial
- Associated Therapies
- -
Strategies to Reduce Mortality Among HIV-infected and HIV-exposed Children Admitted With Severe Acute Malnutrition
- Conditions
- Interventions
- First Posted Date
- 2021-09-21
- Last Posted Date
- 2021-09-30
- Lead Sponsor
- Makerere University
- Target Recruit Count
- 300
- Registration Number
- NCT05051163
- Locations
- 🇺🇬
Makerere University College of Health Sciences, Kampala, Central, Uganda
Trial Comparing Ceftriaxone Plus Azithromycin Versus Ceftriaxone for the Treatment of Gonorrhea
- First Posted Date
- 2021-08-30
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- Institute of Tropical Medicine, Belgium
- Target Recruit Count
- 42
- Registration Number
- NCT05027516
- Locations
- 🇧🇪
Institute of Tropical Medicine, Antwerpen, Belgium
Assessing Parenteral Antibiotics Versus Single-time Intra-operative Intra-dermal Antibiotic Administration for Prevention of SSI
- Conditions
- Interventions
- First Posted Date
- 2021-07-26
- Last Posted Date
- 2021-07-26
- Target Recruit Count
- 250
- Registration Number
- NCT04975945
- Locations
- 🇮🇳
Grant Government Medical College and Sir JJ Hospital, Mumbai, Maharashtra, India
Experimental Human Infection With Neisseria Gonorrhoeae (LptA Trial)
- First Posted Date
- 2021-05-03
- Last Posted Date
- 2021-12-02
- Target Recruit Count
- 16
- Registration Number
- NCT04870138
- Locations
- 🇺🇸
University of North Carolina Health Care - Infectious Diseases, Chapel Hill, North Carolina, United States
Prophylactic Antibiotics in Admitted Cirrhotics
- First Posted Date
- 2020-01-06
- Last Posted Date
- 2023-03-03
- Lead Sponsor
- Beth Israel Deaconess Medical Center
- Target Recruit Count
- 32
- Registration Number
- NCT04218695
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Ceftriaxone as Home IV for Staph Infections
- First Posted Date
- 2019-10-28
- Last Posted Date
- 2019-10-28
- Lead Sponsor
- Vancouver Island Health Authority
- Target Recruit Count
- 310
- Registration Number
- NCT04141787
- Locations
- 🇨🇦
Royal Jubilee Hospital, Victoria, British Columbia, Canada
🇨🇦Victoria General Hospital, Victoria, British Columbia, Canada
A Study to Compare Different Antibiotics and Different Modes of Fluid Treatment for Children With Severe Pneumonia
- First Posted Date
- 2019-08-01
- Last Posted Date
- 2024-07-08
- Lead Sponsor
- University of Oxford
- Target Recruit Count
- 4392
- Registration Number
- NCT04041791
- Locations
- 🇰🇪
Machakos Level 5 Hospital, Machakos, Kenya
A Study Evaluating Efficacy and Safety of Gepotidacin Compared With Ceftriaxone Plus Azithromycin in the Treatment of Uncomplicated Urogenital Gonorrhea
- Conditions
- Interventions
- First Posted Date
- 2019-07-08
- Last Posted Date
- 2024-05-30
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 628
- Registration Number
- NCT04010539
- Locations
- 🇬🇧
GSK Investigational Site, St Helens, United Kingdom
Zoliflodacin in Uncomplicated Gonorrhoea
- Conditions
- Interventions
- First Posted Date
- 2019-05-22
- Last Posted Date
- 2024-07-26
- Target Recruit Count
- 1011
- Registration Number
- NCT03959527
- Locations
- 🇺🇸
Public Health - Seattle & King County STD Clinic, Seattle, Washington, United States
🇺🇸Jefferson County Department of Health, Birmingham, Alabama, United States
🇺🇸University of Alabama at Birmingham, Birmingham, Alabama, United States
Experimental Human Infection With Neisseria Gonorrhoeae
- First Posted Date
- 2019-02-15
- Last Posted Date
- 2021-03-23
- Target Recruit Count
- 27
- Registration Number
- NCT03840811
- Locations
- 🇺🇸
University of North Carolina Health Care - Infectious Diseases, Chapel Hill, North Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.